Nurix Therapeutics (NASDAQ:NRIX) Receives Overweight Rating from Stephens

Stephens reissued their overweight rating on shares of Nurix Therapeutics (NASDAQ:NRIX) in a report released on Monday, Benzinga reports. The firm currently has a $31.00 price objective on the stock.

A number of other equities analysts have also recently issued reports on NRIX. Needham & Company LLC reissued a buy rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research report on Monday. Barclays increased their price objective on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an overweight rating in a research report on Monday, July 15th. HC Wainwright raised their price target on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a buy rating in a research report on Tuesday, June 18th. Royal Bank of Canada raised their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an outperform rating in a research report on Friday, July 12th. Finally, Truist Financial assumed coverage on shares of Nurix Therapeutics in a research report on Wednesday, July 31st. They issued a buy rating and a $36.00 price target on the stock. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $28.71.

Nurix Therapeutics Trading Up 6.5 %

Shares of Nurix Therapeutics stock opened at $25.16 on Monday. The business has a 50-day moving average price of $23.36 and a two-hundred day moving average price of $19.35. Nurix Therapeutics has a 1-year low of $4.22 and a 1-year high of $26.31. The company has a market cap of $1.24 billion, a P/E ratio of -8.62 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). The firm had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. Equities research analysts forecast that Nurix Therapeutics will post -2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the transaction, the chief financial officer now owns 31,002 shares of the company’s stock, valued at $781,870.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Gwenn Hansen sold 3,408 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $70,443.36. Following the completion of the sale, the insider now owns 45,150 shares in the company, valued at $933,250.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.22, for a total transaction of $504,400.00. Following the sale, the chief financial officer now owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,815 shares of company stock valued at $1,424,931 in the last 90 days. 7.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Several large investors have recently modified their holdings of NRIX. GAMMA Investing LLC increased its stake in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Nurix Therapeutics in the 1st quarter valued at approximately $123,000. China Universal Asset Management Co. Ltd. grew its stake in Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after buying an additional 3,793 shares in the last quarter. ProShare Advisors LLC grew its stake in Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after buying an additional 998 shares in the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in Nurix Therapeutics in the 2nd quarter valued at approximately $201,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.